{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Study Design (continued):', 'Treatment Period in Study HZNP-TEP-301 and are proptosis non-responders or were proptosis responders at', 'Week 24 but meet the criteria for re-treatment due to relapse (see Section 9.3.4) during the Follow-Up Period of', 'HZNP-TEP-301 will be eligible for enrollment. The study treatment previously administered in HZNP-TEP-301', '(teprotumumab or placebo) will remain masked throughout this extension study.', 'All subjects who choose to participate will receive 8 infusions of teprotumumab (10 mg/kg for the first infusion', 'followed by 20 mg/kg for the remaining 7 infusions) in an open-label fashion. The Baseline (Day 1) Visit of this', 'extension study will occur within 14 days after the final visit of Study HZNP-TEP-301 (Week 24 for proptosis', 'non-responders and up to Week 72 for subjects who relapse). During the open-label Treatment Period, study', 'drug infusions are scheduled for Day 1 (Baseline), and Weeks 3, 6, 9, 12, 15, 18, and 21 (with a final visit at', 'Week 24 of the 24-Week Treatment Period).', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff, and at any scheduled', 'infusion, the infusion rate may be reduced or the dose may be interrupted or held based on decreased tolerability', '(see Section 9.4.6.3.2 for details). On each dosing day, scheduled assessments (except for adverse event [AE]', 'and concomitant medication use monitoring, which will be monitored throughout the clinic visit) will be', 'completed prior to study drug dosing. After each of the first 2 infusions, subjects will be contacted by', 'phone/email the following day and will return to the clinic 1 week after the infusion (Weeks 1 and 4) for safety', 'and tolerability assessments; additional phone/email contacts and clinic visits may also be conducted for any', 'subject experiencing an infusion-associated event.', 'After completion of the Treatment Period, subjects who were proptosis non-responders in Study HZNP-TEP-', '301 will enter a 24-week Follow-Up Period, during which study drug will not be administered and clinic visits', 'are scheduled for 1, 3, and 6 months (Visits Month 7, 9 and 12) after the Week 24 Visit; if any of these subjects', 'discontinue from the Follow-Up Period prior to the Month 12 Visit, they will return to the clinic and undergo the', 'scheduled Month 12 assessments prior to study discharge. Those who complete the Month 12 Visit will be', 'contacted 6 and 12 months later via phone or email by research staff to enquire if any treatment for TED has', 'been received since last study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', 'Subjects who relapse during the Follow-Up Period of HZNP-TEP-301 and choose to enter this extension study', 'will not participate in the Follow-Up Period. For these subjects, the last clinic visit is at Week 24. Those who', 'complete the Week 24 Visit will be contacted 6 and 12 months later via phone or email by research staff to', 'enquire if any treatment for TED has been received since last study contact. If yes, subject will be questioned', 'regarding type of treatment and outcome/response.', 'An overview of the study design is presented in the schematic below, and details of study activities are provided', 'in Section 2.1, Schedule of Assessments.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 31 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Subjects who were proptosis non-responders in Study HZNP-TEP-301', 'Teprotumumab Open-Label Treatment Period\u00b9', 'Follow-Up Period', 'Follow-Up Contact4', '24 Weeks\u00b2', '24 Weeks\u00b3', '48 Weeks', 'Clinic Visits', 'Day 15,6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W247', 'W28', 'W36', 'W488', 'W72', 'W96', 'Baseline', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M18', 'M24', 'Study Week/Month', 'Subjects who relapsed in Study HZNP-TEP-301', 'Teprotumumab Open-Label Treatment Period\u00b9', 'Follow-Up Contact4', '24 Weeks\u00b2', '48 Weeks', 'Clinic Visits', 'Day 15,6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W247', 'W48', 'W72', 'Baseline', 'M1', 'M3', 'M6', 'M12', 'M18', 'Study Week/Month', '* Infusion of study drug. M=Month; W=Week.', '1.', 'Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions).', '2. Visit windows are 1 day for Weeks 1 and 4, 3 days for Weeks 3, 6, 9, 12, 15, 18, and 21, and 7 days for Week 24.', '3.', 'Visit windows of 7 days.', '4.', 'Proptosis non-responders from Study HZNP-TEP-301 who complete the Month 12 Visit and subjects who relapsed during the Follow-Up', 'Period of HZNP-TEP-301 and complete the Week 24 Visit.', '5.', 'Visit must occur within 14 days after the final visit of HZNP-TEP-301.', '6. Subjects will be contacted by phone/email the day following the first and second infusions for safety and tolerability assessments;', 'phone/email contacts will also occur the day after any clinic visit where a subject experiences an infusion-related AE.', '7.', 'If a subject wishes to discontinue dosing, the subject will return to the clinic and undergo the scheduled Week 24 assessments.', '8.', 'If a subject participates in the Follow-Up Period and prematurely discontinues prior to Month 12, he/she will return to the clinic and', 'undergo the Month 12 assessments prior to study discharge.', 'Subject Population:', 'Subjects with TED who complete the 24-week double-masked Treatment Period in HZNP-TEP-301 and are', 'proptosis non-responders (<2 mm reduction in proptosis in the study eye) or were proptosis responders at', 'Week 24 in study HZNP-TEP-301 but who meet criteria for re-treatment due to relapse during the Follow-Up', 'Period are eligible to enter this open-label extension study.', 'Inclusion Criteria:', 'Eligible subjects must meet/provide all of the following criteria:', '1. Written informed consent.', '2. Completed the 24-week double-masked Treatment Period in Study HZNP-TEP-301.', '3. Proptosis non-responder (<2 mm reduction in proptosis in the study eye) at Week 24 of Study HZNP-', 'TEP-301 OR proptosis responder at Week 24 who relapses (see Section 9.3.4) during the Follow-Up', 'Period of Study HZNP-TEP-301.', '4.', 'Subject must be euthyroid with the baseline disease under control, or have mild hypo- or', 'hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3] levels < 50% above', 'or below the normal limits) at the most recent clinic visit. Every effort should be made to correct the', 'mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state for the full duration of the', 'clinical trial.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 32 of 118']\n\n###\n\n", "completion": "END"}